CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of p53-targeted small molecule agnostic therapies, has today announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors. Dr. Gallagher brings more than 30 years of biotechnology leadership and expertise in drug development and commercialization. She replaces Thilo Schroeder, Ph.D., who is leaving the board. Changes to the Board of Directors are effective immediately.
“We are delighted to welcome Carol to our Board of Directors. She is a recognized industry leader with an outstanding track record of value creation. His capabilities in drug development and commercialization as well as his extensive board experience will be invaluable to the future growth and success of PMV,” said David Mack, Ph.D., President and Chief management (CEO). “I would also like to thank Thilo for his many contributions to PMV and we wish him the best in his current and future endeavours.”
Dr. Gallagher is a veteran board director and is currently a venture capital partner at New Enterprise Associates (NEA), a global venture capital firm. Over the past ten years, she has been a director of several public and private companies. She is currently a Director at Atara Biotherapeutics and Frazier Lifesciences Acquisition Corp and until recently, Turning Point Therapeutics which was acquired by Bristol Myers Squibb in August 2022. From 1989 to 2011, she held positions of increasing responsibility within Eli Lilly, Amgen, Agouron Pharmaceuticals, Pfizer, Idec Pharmaceuticals, CancerVax and Anadys Pharmaceuticals. From 2008 to 2011, she was CEO of Calistoga Pharmaceuticals, where she led its successful acquisition by Gilead Sciences in 2011. She attended Vanderbilt University and earned a Bachelor of Science and Doctor of Pharmacy degree from the University of Kentucky College of Pharmacy.
Dr. Gallagher commented: “It is an exciting time at PMV, particularly with the recent clinical confirmation of the proof of concept of its lead candidate PC14586 as a monotherapy to selectively reactivate p53 in multiple tumor types. I am honored to join the PMV Board of Directors and look forward to working with the leadership team and fellow Board members to advance PMV’s mission to develop tumor-agnostic p53 targeted therapies. that can benefit patients for whom new treatment options are badly needed.
PC14586 is a first-in-class small molecule p53 reactivator designed to selectively bind to the crevice present in the mutant p53 protein Y220C, thereby restoring the structure of the wild-type or normal p53 protein and the function of suppressing them. tumors. In October 2020, the United States Food and Drug Administration granted Fast Track Designation to PC14586 for the treatment of patients with locally advanced or metastatic solid tumors with a p53 Y220C mutation. For more information about the PYNNACLE Phase 1/2 trial (PMV-586-101), see www.clinicaltrials.gov (NCT study ID NCT04585750).
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. Mutations in p53 are found in about half of all cancers. The field of p53 biology was created by our co-founder Arnold Levine, Ph.D., when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines a unique biology-driven understanding of pharmaceutical development. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
PMV Pharmaceuticals, Inc.